KARL STORZ GmbH & Co. KG.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From KARL STORZ GmbH & Co. KG.
Among other Asia deals, Takeda adds to pair of recent gene therapy tie-ups with a CNS-focused cell therapy partnership with Immusoft; earlier it licensed ex-US rights to JCR’s Hunter syndrome drug.
The global market for arthroscopy products and sports medicine implants is expected to reach $6.3bn by 2025, a CAGR of 1.9% from $5.7bn in 2020. The growth is driven partly by rising arthroscopy procedure volumes, expanding indications for joint repair, and patient preference for minimally invasive procedures. COVID-19 and downward pressures on device prices are among the growth barriers.
The US FDA says it has received more than 450 Medical Device Reports since 2017 that describe patient infections following use of reprocessed cystoscopes, ureteroscopes and cystourethroscopes. Three deaths were reported by Olympus Corp.
The global market for endoscopic and pelvic surgery procedures is expected to reach $17.7bn in 2023, a CAGR of 6.4%, driven by patients' demand for less invasive surgeries and physicians' preference for minimally invasive surgeries versus open surgeries. By 2023, the number of general and pelvic endoscopic procedures performed globally will reach about 29.7 million, representing a CAGR of 3.6%.
- Medical Devices
- Consumables, Central Supplies
- Implantable Devices
- Infection Control-Sterilization
- Infusion Therapy Equipment and Supplies
- Monitoring Equipment & Devices
- Radiofrequency Devices
- Rehabilitation Equipment and Devices
- Surgical Equipment & Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
- KARL STORZ Endoscopy-America, Inc.